Aligos Therapeutics (STU:5WK0) Construction In Progress: €0.00 Mil (As of Mar. 2026)


STU:5WK0 Aligos Therapeutics Inc STU:5WK0
25 GF Score
Price €5.11
GF Value €2.11
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics Construction In Progress?

Aligos Therapeutics STU:5WK0 -4.13% 25 Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:5WK0 with a GF Score™ of 25/100 and a GF Value™ of €2.11 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Aligos Therapeutics's quarterly construction in progress declined from Sep. 2025 (€0.14 Mil) to Dec. 2025 (€0.00 Mil) but then stayed the same from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil).

Aligos Therapeutics's annual construction in progress stayed the same from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Aligos Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics Construction In Progress Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 0.02 0.02 0.00 0.00 0.00

Aligos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.14 0.00 0.00
STU:5WK0
25GF Score
Aligos Therapeutics Inc STU:5WK0
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aligos Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
Aligos Therapeutics (STU:5WK0) has a Construction In Progress of €0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Aligos Therapeutics and its competitors.
Is Aligos Therapeutics' Construction In Progress too high?
Aligos Therapeutics' current Construction In Progress is €0.00 Mil. Overall, Aligos Therapeutics has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Construction In Progress compare to SNTI and NTRB?
Aligos Therapeutics' Construction In Progress of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (STU:5WK0) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.11, compared to a current price of €5.11 — trading 142.2% above its estimated fair value. The current Construction In Progress is €0.00 Mil. Aligos Therapeutics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Aligos Therapeutics (STU:5WK0), the current Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (STU:5WK0) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of €5.11 is trading 142.2% above its estimated GF Value™ of €2.11. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:5WK0:

  • Construction In Progress: €0.00 Mil
  • GF Value™: €2.11 vs. price of €5.11 (142.2% above fair value)
  • GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the STU:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges ALGS:USA
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
25GF Score

Get the complete analysis for STU:5WK0

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.11
Price
€2.11
GF Value